Insider Transactions in Q1 2024 at Altimmune, Inc. (ALT)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 02
2024
|
Vipin K Garg President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
8,376
-2.79%
|
$75,384
$9.32 P/Share
|
|
Feb 02
2024
|
Vipin K Garg President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
18,950
+5.93%
|
-
|
|
Feb 02
2024
|
Matthew Scott Harris Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,332
-4.17%
|
$20,988
$9.32 P/Share
|
|
Feb 02
2024
|
Matthew Scott Harris Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,775
+12.2%
|
-
|
|
Feb 02
2024
|
M Scot Roberts Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,330
-5.18%
|
$20,970
$9.32 P/Share
|
|
Feb 02
2024
|
M Scot Roberts Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,775
+14.74%
|
-
|
|
Feb 01
2024
|
Vipin K Garg President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
7,313
-2.53%
|
$65,817
$9.88 P/Share
|
|
Feb 01
2024
|
Vipin K Garg President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
16,545
+5.42%
|
-
|
|
Feb 01
2024
|
Matthew Scott Harris Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,801
-3.6%
|
$16,209
$9.88 P/Share
|
|
Feb 01
2024
|
Matthew Scott Harris Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,166
+10.98%
|
-
|
|
Feb 01
2024
|
M Scot Roberts Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,801
-4.62%
|
$16,209
$9.88 P/Share
|
|
Feb 01
2024
|
M Scot Roberts Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,166
+13.65%
|
-
|
|
Jan 31
2024
|
Richard I Eisenstadt Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,621
+9.31%
|
$9,242
$2.69 P/Share
|
|
Jan 31
2024
|
Vipin K Garg President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
7,889
+2.82%
|
$15,778
$2.69 P/Share
|
|
Jan 31
2024
|
Matthew Scott Harris Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,257
+6.92%
|
$6,514
$2.69 P/Share
|
|
Jan 31
2024
|
Raymond M Jordt Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,030
+26.79%
|
$10,060
$2.69 P/Share
|
|
Jan 31
2024
|
M Scot Roberts Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,860
+15.14%
|
$11,720
$2.69 P/Share
|
|
Jan 30
2024
|
Richard I Eisenstadt Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,175
-5.11%
|
$19,575
$9.8 P/Share
|
|
Jan 30
2024
|
Richard I Eisenstadt Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,275
+17.89%
|
-
|
|
Jan 30
2024
|
Vipin K Garg President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
11,697
-4.24%
|
$105,273
$9.8 P/Share
|
|
Jan 30
2024
|
Vipin K Garg President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
26,775
+8.84%
|
-
|
|
Jan 30
2024
|
Matthew Scott Harris Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,709
-6.26%
|
$24,381
$9.8 P/Share
|
|
Jan 30
2024
|
Matthew Scott Harris Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,275
+17.65%
|
-
|
|
Jan 30
2024
|
M Scot Roberts Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,709
-9.12%
|
$24,381
$9.8 P/Share
|
|
Jan 30
2024
|
M Scot Roberts Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,275
+23.8%
|
-
|
|
Jan 01
2024
|
Raymond M Jordt Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,503
-22.33%
|
$27,533
$11.25 P/Share
|
|
Jan 01
2024
|
Raymond M Jordt Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,375
+45.55%
|
-
|